ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT:BTX) today announced that it has closed the equity financing it announced on June 3, 2013 and received gross proceeds of $9,057,966. BioTime intends to use the net proceeds from the sale of its common shares and warrants for working capital and other general corporate purposes, and may invest a portion of the proceeds in one or more of its subsidiaries, including funding of the expansion of the LifeMap Sciences, Inc. product development and research programs. The common shares and warrants, and the shares issuable upon exercise of the warrants, were sold pursuant to a prospectus supplement dated as of June 3, 2013, which has been filed with the Securities and Exchange Commission (SEC) in connection with a takedown from the Companys shelf registration statement on Form S-3 (File No. 333-183557), which became effective on September 7, 2012, and the base prospectus dated September 7, 2012. Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SECs website at http://www.sec.gov. About BioTime, Inc. BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is … Continue reading →

Posted Friday, June 07, 2013-9:45 am Researchers from UCLAs Department of Obstetrics and Gynecology have isolated a new population of primitive, stress-resistant human pluripotent stem cells easily derived from fat tissue able to differentiate into virtually every cell type in the human body without genetic modification. The cells, called Multi-lineage Stress-Enduring (Muse-AT) stem cells from fat, or adipose, tissue, were discovered by scientific accident when a piece of equipment failed in the lab, killing all the stem cells in the experiment except for the Muse-AT ones. The research team further discovered that not only are Muse-AT cells able to survive severe stress, they may even be activated by it, said study senior author Gregorio Chazenbalk, an associate researcher with UCLA Obstetrics and Gynecology. These pluripotent cells, isolated from fat tissue removed during liposuction, expressed many embryonic stem cell markers and were able to differentiate into muscle, bone, fat, cardiac, neuronal and liver cells. An examination of genetic characteristics confirmed their specialized functions, as well as a capacity to regenerate tissue when transplanted back into the body following their awakening. This population of cells lies dormant in the fat tissue until subjected to very harsh conditions. These cells can survive in … Continue reading →